http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2420287

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't
endingPage 2613
issn 1522-9645
0195-668X
issueIdentifier 21
pageRange 2601-2613
publicationName European Heart Journal
startingPage 2601
bibliographicCitation Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL; J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J. 2010 Nov;31(21):2601–13. PMID: 20805115; PMCID: PMC2966970.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d033031b5a101fc920c0e6c385d722df
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_93fb7932d40a04d18978f3207f1bd6ad
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0f4a3c7633505ee9d01cd0bd5a391340
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f42d4ec57d32e5f9a70a3ebf169fde10
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_283642476df22e2f920f3a0c95a983dc
date 2010-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/20805115
https://doi.org/10.1093/eurheartj/ehq320
https://pubmed.ncbi.nlm.nih.gov/PMC2966970
isPartOf https://portal.issn.org/resource/ISSN/0195-668X
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3586
https://portal.issn.org/resource/ISSN/1522-9645
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
discusses http://id.nlm.nih.gov/mesh/M0283418
http://id.nlm.nih.gov/mesh/M0011054
http://id.nlm.nih.gov/mesh/M0535447
http://id.nlm.nih.gov/mesh/M0018233
http://id.nlm.nih.gov/mesh/M0017012
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D044463Q000037
http://id.nlm.nih.gov/mesh/D054058Q000188
http://id.nlm.nih.gov/mesh/D003324Q000188
http://id.nlm.nih.gov/mesh/D011725Q000008
http://id.nlm.nih.gov/mesh/D007097Q000008
http://id.nlm.nih.gov/mesh/D010975Q000008
hasSubjectTerm http://id.nlm.nih.gov/mesh/D004311
http://id.nlm.nih.gov/mesh/D008133Q000139
http://id.nlm.nih.gov/mesh/D006470Q000139
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D056486Q000209
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D000284
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7065
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_a5f903d410706bb5100ce8d54716bcab
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11015
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10459564
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7969
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7346

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127719861
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127968075
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128918298
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247988848
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128926582
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127563695
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127638306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID243850853
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129046631
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129772675

Total number of triples: 61.